Saskatchewan Health Concerns, Knee Pain Therapy, and Alzheimer's Drug Approval
In this episode, Dr. Chi-Ming Chow welcomes listeners and introduces the day's topics, which cover a range of significant healthcare issues. He begins by discussing concerns raised by healthcare workers in Saskatchewan, focusing on software issues impacting their work. The conversation then shifts to a study on the effectiveness of physical therapy for knee pain, highlighting its potential benefits. Dr. Chow examines the FDA's initiative to make biotech drugs more affordable, shedding light on its implications for patients. He also delves into the controversy surrounding Quebec's doctor remuneration system. The episode concludes with the approval of the Alzheimer's drug lecanemab by Health Canada, exploring its potential impact on treatment options.
Key Points
- Health-care workers in Saskatchewan rallied to demand better working conditions, fair wages, and a new contract, highlighting the critical issues in the province's healthcare sector.
- A new study in the New England Journal of Medicine found that adding in-clinic physical therapy to home exercise does not significantly reduce knee pain from degenerative meniscal tears compared to home exercise alone.
- Health Canada has approved lecanemab, the first drug in over a decade to slow the progression of Alzheimer's disease by targeting its underlying biology, though its use is limited to individuals without the APOE4 gene.
Chapters
| 0:00 | |
| 0:29 | |
| 7:09 | |
| 10:29 | |
| 13:08 | |
| 16:49 |
Transcript
Loading transcript...